INCLUSION CRITERIA FOR SCREENING (STEP 0 - PREREGISTRATION)Xx_NEWLINE_xXINCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1)Xx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIA:Xx_NEWLINE_xXREGISTRATION INCLUSION CRITERIA:Xx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Radiographically measurable diseaseXx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Radiographically measurable diseaseXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: ECOG performance status 0 or 1Xx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Hemoglobin >= 9.0 g/dLXx_NEWLINE_xXInclusion criteria associated with type and status of lymphomaXx_NEWLINE_xXINCLUSION CRITERIA ASSOCIATED WITH HIV-1 STATUSXx_NEWLINE_xXGENERAL INCLUSION CRITERIA (TIMELINE: 8 WEEKS PRIOR TO START OF TRIAL, UNLESS OTHERWISE SPECIFIED)Xx_NEWLINE_xXINCLUSION CRITERIA - STRATUM A:Xx_NEWLINE_xXINCLUSION CRITERIA - STRATUM BXx_NEWLINE_xXSOLID TUMOR INCLUSION CRITERIA:Xx_NEWLINE_xXNON-HODGKIN LYMPHOMA INCLUSION CRITERIA:Xx_NEWLINE_xXINCLUSION CRITERIA FOR BLOOD PROCUREMENT:Xx_NEWLINE_xXINCLUSION CRITERIA FOR T CELL TREATMENT:Xx_NEWLINE_xXPHASE I INCLUSION CRITERIAXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: ECOG performance status of 0-1Xx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Hemoglobin > 9 g/dLXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Platelet counts > 100 x 10^9/LXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Serum bilirubin < 2 x ULNXx_NEWLINE_xXPHASE II INCLUSION CRITERIA: Women must not be pregnant or breastfeedingXx_NEWLINE_xXTo be eligible for participation in the study, patients must meet all of the following inclusion criteria:Xx_NEWLINE_xXRefusal to use effective methods of contraception (see inclusion criteria for details).Xx_NEWLINE_xXSTEP 2 SCREENING INCLUSION CRITERIA FOR LMS PATIENTS:Xx_NEWLINE_xXPROCUREMENT INCLUSION CRITERIA: Hemoglobin (Hgb) > 8.0 (transfusions allowed)Xx_NEWLINE_xXTREATMENT INCLUSION CRITERIAXx_NEWLINE_xXIf applicable, use of contraception methods or abstinence as defined by the protocol Study-Drug Specific Inclusion Criteria: Trastuzumab plus PertuzumabXx_NEWLINE_xXAdditional Patient Inclusion Criteria for Patients Assigned to Double Umbilical Cord Blood Arm:Xx_NEWLINE_xXSPECIFIC INCLUSION CRITERIA FOR PRE-SURGICAL COHORT:Xx_NEWLINE_xXSPECIFIC INCLUSION CRITERIA FOR EXPANSION COHORT:Xx_NEWLINE_xXINCLUSION CRITERIA FOR PRE-REGISTRATION (PATIENTS WITH UNKNOWN HER2 MUTATION STATUS TO HAVE TUMOR TISSUE SCREENED):Xx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Agree to provide archival tumor material for researchXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): ECOG performance status =< 2Xx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Serum creatinine: =< 1.5 x ULN within 2 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Total bilirubin: =< 1.5 x ULN (in case of known Gilbert’s syndrome, < 2 x ULN is allowed) within 2 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Presence of disease progression on the most recent disease evaluationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): There is no limitation on the number of prior lines of systemic therapyXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): ECOG performance status =< 2Xx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Serum creatinine: =< 1.5 x ULN within 2 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Total bilirubin: =< 1.5 x ULN (in case of known Gilbert’s syndrome, < 2 x ULN is allowed) within 2 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of disease progression on the most recent disease evaluationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): LVEF >= institutional LLN within 4 weeks of registrationXx_NEWLINE_xXINCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): There is no limitation on the number of prior lines of systemic therapyXx_NEWLINE_xXFor enrollment into the China extension cohort, residence in the People's Republic of China Disease-specific Inclusion Criteria:Xx_NEWLINE_xXParticipant agrees not to participate in another interventional study while on treatment. Randomization Inclusion CriteriaXx_NEWLINE_xXOther Inclusion Criteria May Apply.Xx_NEWLINE_xXINCLUSION - PROCUREMENT: Weighs at least 12 kgXx_NEWLINE_xXBlood transfusion to meet the inclusion criteria will be allowedXx_NEWLINE_xXPatients who do not meet inclusion criteriaXx_NEWLINE_xXADDITIONAL EXPANSION COHORT SUBJECT INCLUSION CRITERIAXx_NEWLINE_xXPatients with cancer of unknown primary or a rare tumor (i.e., fewer than 15 cases per 100,000 per year) with no approved therapies; (patients in this inclusion criteria must meet all other exclusion and inclusion criteria except inclusion criteria #1)Xx_NEWLINE_xXFurther inclusion criteria applyXx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIA:Xx_NEWLINE_xXREGISTRATION/RANDOMIZATION INCLUSION CRITERIA:Xx_NEWLINE_xXPreoperative inclusion:Xx_NEWLINE_xXIntraoperative inclusion:Xx_NEWLINE_xXINCLUSION CRITERIA FOR STRATA A, B, D AND EXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patient must have completed immunotherapy (e.g. tumor vaccines, oncolytic viruses, etc.) at least 42 days prior to enrollmentXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: All races and ethnic groups are eligible for this studyXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patients with neurological deficits should have deficits that are completely stable for a minimum of 1 week (7 days) prior to enrollmentXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Albumin >= 2 g/dlXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Pulse oximetry > 93% on room air and no evidence of dyspnea at restXx_NEWLINE_xXPatient has a WHO performance status 0-2. Patients in Arm 1 to 4 must also meet the following inclusion criteria:Xx_NEWLINE_xXPROCUREMENT INCLUSION CRITERIA: Patients with life expectancy ? 6 weeksXx_NEWLINE_xXPROCUREMENT INCLUSION CRITERIA: Hemoglobin (Hgb) > 8.0 (transfusions allowed)Xx_NEWLINE_xXTREATMENT INCLUSION CRITERIAXx_NEWLINE_xXDONOR INCLUSION:Xx_NEWLINE_xXTREATMENT INCLUSIONXx_NEWLINE_xXRETREATMENT WITH MODIFIED T-CELLS INCLUSION CRITERIA: Subject has modified T cell product available for releaseXx_NEWLINE_xXRETREATMENT WITH MODIFIED T-CELLS INCLUSION CRITERIA: Subject has < 5 % detectable modified T cells in peripheral blood (can be done at any time prior)Xx_NEWLINE_xXRETREATMENT WITH MODIFIED T-CELLS INCLUSION CRITERIA: Oxygen saturation 90% or higher on room airXx_NEWLINE_xXRETREATMENT WITH MODIFIED T-CELLS INCLUSION CRITERIA: ALT (SGPT): =< 5 x ULNXx_NEWLINE_xXHematologic inclusion within 2 weeks of start of treatmentXx_NEWLINE_xXHepatic inclusion within 2 weeks of entryXx_NEWLINE_xXINCLUSION - TREATMENT: Bilirubin ? 3xXx_NEWLINE_xXINCLUSION CRITERIA FOR NK CELL DONORXx_NEWLINE_xXINCLUSION CRITERIA FOR SELECTED NK CELL DONORXx_NEWLINE_xXINCLUSION CRITERIA TO ENROLL AND PREPARE CELLS FOR SHIPPING TO UNIVERSITY OF MINNESOTA (UMN) FOR PROCESSINGXx_NEWLINE_xXINCLUSION CRITERIA FOR ELIGIBILITY TO RECEIVE TREATMENTXx_NEWLINE_xXPATIENT-SPECIFIC INCLUSION CRITERIAXx_NEWLINE_xXFailure to meet any of the criteria set forth in the inclusion criteria sectionXx_NEWLINE_xXSCREENING PHASE INCLUSION CRITERIAXx_NEWLINE_xXPatients may take steroids for disease control up to 24 hours prior to study enrollment; topical steroids are allowed for CTCL patients as described in inclusion criteria aboveXx_NEWLINE_xXOther inclusion criteria may applyXx_NEWLINE_xXPatient with bilateral LG UTUC may be enrolled if at least one side meets the inclusion criteria for the trial and if the other kidney does not require further treatments (The other kidney can be treated prior to the beginning of the study).Xx_NEWLINE_xXSignificant organ dysfunction, not meeting inclusion criteriaXx_NEWLINE_xXAll patients must meet the following inclusion and exclusion criteria; NO EXCEPTIONS WILL BE GIVENXx_NEWLINE_xXARM I INCLUSION CRITERIA: There are no restrictions on the number of prior lines of treatment for systemic diseaseXx_NEWLINE_xXINCLUSION CRITERIA FOR DOSE ESCALATION COHORTXx_NEWLINE_xXADDITIONAL INCLUSION CRITERIA FOR DOSE EXPANSION COHORTXx_NEWLINE_xXOther protocol defined inclusion criteria could apply.Xx_NEWLINE_xXINCLUSION CRITERIA FOR URINARY SCREENINGXx_NEWLINE_xXINCLUSION CRITERIA FOR TREATMENTXx_NEWLINE_xXSCREENING INCLUSION CRITERIAXx_NEWLINE_xXPlatelet count > 100000/mm^3; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXRECIPIENT INCLUSION CRITERIAXx_NEWLINE_xXADDITIONAL INCLUSION CRITERION FOR COHORT 4 (CUTANEOUS HNSCC):Xx_NEWLINE_xXOTHER INCLUSION CRITERIA:Xx_NEWLINE_xXADDITIONAL INCLUSION CRITERIA PERTINENT ONLY FOR PATIENTS WITH PRIOR ALLOGENEIC TRANSPLANTATION:Xx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: ECOG PS of 0 or 1Xx_NEWLINE_xXPRE-REGISTRATION- INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION- INCLUSION CRITERIAXx_NEWLINE_xXINCLUSION CRITERIA FOR GENETICS RESEARCH STUDY (OPTIONAL)Xx_NEWLINE_xXSTEP 1 SCREENING INCLUSION CRITERIAXx_NEWLINE_xXSTEP 2 SCREENING INCLUSION CRITERIAXx_NEWLINE_xXWithin 3 weeks of any corticosteroids except per inclusion criteria aboveXx_NEWLINE_xXCOHORT 2 INCLUSION CRITERIAXx_NEWLINE_xXFurther inclusion criteria applyXx_NEWLINE_xXEach patient must be positive for HLA-A*02 and meet all of the following inclusion criteria to be enrolled in the studyXx_NEWLINE_xXPART 1 INCLUSION CRITERIAXx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: These criteria must be met by all subjects, regardless of bone marrow involvement with tumorXx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA: Shortening Fraction > 27%Xx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: Hgb >= 8 g/dL (may receive RBC transfusion)Xx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: These criteria must be met by all subjects, regardless of bone marrow involvement with tumorXx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: SGPT (ALT) =< 110 U/L; for the purpose of this study, the ULN for SGPT is 45 U/LXx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: Shortening Fraction > 27%Xx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: Hgb >= 8 g/dL (may receive RBC transfusion)Xx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: These criteria must be met by all subjects, regardless of bone marrow involvement with tumorXx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: Shortening Fraction > 27%Xx_NEWLINE_xXDRUG-SPECIFIC INCLUSION CRITERIAXx_NEWLINE_xXINCLUSION CRITERIA (ENROLLMENT)Xx_NEWLINE_xXINCLUSION CRITERIA (TRANSPLANT)Xx_NEWLINE_xXPANOBINOSTAT MAINTENANCE INCLUSIONXx_NEWLINE_xXINCLUSION CRITERIA FOR SCREENING:Xx_NEWLINE_xXINCLUSION CRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION:Xx_NEWLINE_xXINCLUSION CRITERIA FOR LYMPHODEPLETION CHEMOTHERAPY, JCAR014 AND DURVALUMAB:Xx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH CLL, MCL OR ALL (COHORT A)Xx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): ROR1 expression in > 20% of the primary tumor or metastasis by immunohistochemistry (IHC)Xx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusionXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Ability to understand and provide informed consentXx_NEWLINE_xXINCLUSION CRITERIA FOR TNBC: Patients may receive agents to protect against skeletal related complications such as zoledronic acid or denosumabXx_NEWLINE_xXINCLUSION CRITERIA FOR TNBC: ROR1 expression in > 20% of the primary tumor or metastasis by IHCXx_NEWLINE_xXINCLUSION CRITERIA FOR TNBC: Patients must be off chemotherapy for a minimum of 3 weeks prior to planned leukapheresisXx_NEWLINE_xXINCLUSION CRITERIA FOR TNBC: Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusionXx_NEWLINE_xXPatients must have baseline evaluations performed prior to the first dose of study drug and must meet all inclusion and exclusion criteriaXx_NEWLINE_xXBlood transfusion to meet the inclusion criteria will be allowedXx_NEWLINE_xXDOSE EXPANSION PHASE ADDITIONAL INCLUSION CRITERIAXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Documentation of absence of activating and targetable BRAF or NRAS point mutationsXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: ECOG performance status 0-1Xx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Documentation of absence of activating and targetable BRAF or NRAS point mutationsXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Platelets >= 75 x 10^9/LXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Serum amylase =< 2 x ULNXx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: ECOG performance status 0-1Xx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Documentation of absence of activating and targetable BRAF or NRAS point mutationsXx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Hemoglobin >= 9 g/dLXx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: ECOG performance status 0-2Xx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Documentation of absence of activating and targetable BRAF or NRAS point mutationsXx_NEWLINE_xXECOG performance status (PS) of 0 or 1 Details and other protocol-defined inclusion criteria may applyXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS ON ALL STRATA EXCEPT STRATUM PXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS TO BE TREATED ON STRATUM AXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS TO BE TREATED ON STRATA B OR CXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS ON STRATUM DXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS ON STRATUM PXx_NEWLINE_xXINCLUSION CRITERIA - PART AXx_NEWLINE_xXFIRST REGISTRATION-INCLUSION:Xx_NEWLINE_xXSECONDARY REGISTRATION-INCLUSION:Xx_NEWLINE_xXINCLUSION CRITERIA - ARM A:Xx_NEWLINE_xXINCLUSION CRITERIA - ARM B:Xx_NEWLINE_xXINDUCTION PHASE INCLUSION CRITERIA:Xx_NEWLINE_xXRESEARCH PHASE INCLUSION CRITERIA: In patients with suspected liver disease, bilirubin must be =< 2.5 mg/dLXx_NEWLINE_xXINCLUSION CRITERIA FOR ENROLLMENT: The patient has been off all immunosuppression for at least 2 weeks at the time of PTCy-MILs collectionXx_NEWLINE_xXINCLUSION CRITERIA FOR ENROLLMENT: Expectation of ability to safely undergo salvage treatment appropriate for the patient’s malignant disease typeXx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: No active acute infectionsXx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: No requirement for systemic steroidsXx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Platelets >= 100,00/uL (transfusions are permitted)Xx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Hemoglobin >= 9.0 g/dL (transfusions are permitted)Xx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: AST (aspartate aminotransferase) =< 3 x ULNXx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: ALT (alanine aminotransferase) =< 3 x ULNXx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Bilirubin =< 1.5 x ULNXx_NEWLINE_xXSCREENING INCLUSION CRITERIAXx_NEWLINE_xXMAIN STUDY COHORT INCLUSION CRITERIA: Scheduled to undergo surgery with either partial or radical nephrectomyXx_NEWLINE_xXSCREENING INCLUSION CRITERIA:Xx_NEWLINE_xXPatient does not meet the requirements for prior ipilimumab treatment listed in inclusion aboveXx_NEWLINE_xXChemotherapy, radiation, or immunotherapy, within 2 weeks prior to study entry, other than those specified in the inclusion criteria (hydroxyurea and hypomethylating agents)Xx_NEWLINE_xXINCLUSION CRITERIA PATIENTS WITH SOLID TUMOR CANCERS AND MELANOMAXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH MALIGNANT MENINGIOMAXx_NEWLINE_xXINCLUSION CRITERIA ALL PATIENTSXx_NEWLINE_xXTREATMENT INCLUSION CRITERIA:Xx_NEWLINE_xXTURNSTILE I INCLUSION CRITERIA:Xx_NEWLINE_xXCHEMOTHERAPY/CELL INFUSION INCLUSION CRITERIA:Xx_NEWLINE_xXCOHORTS 1 AND 2: HEALTHY VOLUNTEERS: Does not meet inclusion criteriaXx_NEWLINE_xXCOHORT 3: ATOPIC DERMATITIS PATIENTS: Does not meet inclusion criteriaXx_NEWLINE_xXINCLUSION CRITERIA FOR OBSERVATION (CONSENT A)Xx_NEWLINE_xXINCLUSION CRITERIA FOR TREATMENT WITH VELIPARIB AND RADIATION (CONSENT B)Xx_NEWLINE_xXPatients with bilateral hydronephrosis unless at least one side has been stented and renal function fulfils the required inclusion criteriaXx_NEWLINE_xXINCLUSION CRITERIA AT TIME OF PROCUREMENT:Xx_NEWLINE_xXINCLUSION CRITERIA AT TIME OF INFUSION:Xx_NEWLINE_xXCentral nervous system (CNS) metastases which do not meet the criteria outlined in the inclusion criteriaXx_NEWLINE_xXRefractory to standard available therapies. Expansion Cohort 1 Specific Inclusion Criteria:Xx_NEWLINE_xXNot eligible for Expansion Cohort 3. Expansion Cohort 2 Specific Inclusion Criteria:Xx_NEWLINE_xXNot eligible for Expansion Cohort 3. Expansion Cohort 3 Specific Inclusion Criteria:Xx_NEWLINE_xXAdditional inclusion criteria existXx_NEWLINE_xXEXCLUSION CRITERIA FOR REGISTRATION: subjects receiving chemotherapy regimens not specified in the inclusion criteriaXx_NEWLINE_xXPROCUREMENT INCLUSION CRITERIA:Xx_NEWLINE_xXTREATMENT INCLUSION CRITERIA:Xx_NEWLINE_xXINCLUSION CRITERIA FOR CD34+ TOPOFF WITHOUT CONDITIONING (COHORT 2):Xx_NEWLINE_xXINCLUSION CRITERIA (ALL COHORTS)Xx_NEWLINE_xXINCLUSION CRITERIA (SUBJECTS STRATIFIED INTO THE THORAX HIGH VOLUME TREATMENT SITE)Xx_NEWLINE_xXPatients with tumor parameters that fall outside of the inclusion criteria above will not be eligibleXx_NEWLINE_xXPatients must be HLA-A2 for cohort A (Turnstile II-Chemotherapy/Cell Infusion-Inclusion Criteria)Xx_NEWLINE_xXPatients must have measurable metastatic melanoma (Turnstile II - Chemotherapy/Cell Infusion -Inclusion Criteria)Xx_NEWLINE_xXSerum creatinine less than or equal to 1.6 mg/dl (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)Xx_NEWLINE_xXINCLUSION CRITERIA FOR NBXx_NEWLINE_xXINCLUSION CRITERIA FOR CCT: age between 1 and 21 years and able to cooperate with radiation safety restrictions during therapy periodXx_NEWLINE_xXINCLUSION CRITERIA FOR CCT: minimum life expectancy of eight weeksXx_NEWLINE_xXSubject must be able to provide an evaluable core or excisional biopsy prior to the start of treatment. Other Inclusion Criteria May ApplyXx_NEWLINE_xXOther inclusion criteria may applyXx_NEWLINE_xXLV mass on CMR > 200 grams (g) Inclusion Criteria for Group 1Xx_NEWLINE_xXHas received 2-6 prior chemotherapy regimens including taxanes in advanced setting Additional Inclusion Criteria for Dose Expansion Part Only:Xx_NEWLINE_xXPatient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria 2Xx_NEWLINE_xXFailure to meet inclusion criteria;Xx_NEWLINE_xXOther inclusion criteria apply.Xx_NEWLINE_xXPATIENT INCLUSION CRITERIA:Xx_NEWLINE_xXDONOR INCLUSION CRITERIA:Xx_NEWLINE_xXREGISTRATION – INCLUSION CRITERIAXx_NEWLINE_xXPRE-REGISTRATION: Determined by study doctor that patient is unlikely to meet inclusion criteria after screening.Xx_NEWLINE_xXEligibility for ASCT is determined by the above inclusion criteria.Xx_NEWLINE_xXOne or more of the inclusion criteria are not metXx_NEWLINE_xXPRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXPRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXADDITIONAL INCLUSION CRITERIA FOR PATIENTS IN COMBINATION FULVESTRANT/CABOZANTINIB COHORTXx_NEWLINE_xXINCLUSION CRITERIA AT TIME OF INITIAL ENROLLMENT:Xx_NEWLINE_xXBlood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXCentral nervous system (CNS) metastases which do not meet the criteria outlined in inclusion criteriaXx_NEWLINE_xXBiopsy does not meet inclusion criteriaXx_NEWLINE_xXOTHER INCLUSION CRITERIA:Xx_NEWLINE_xXPrior systemic cytotoxic therapies for HCC (chemoembolization is permitted if inclusion criteria are met)Xx_NEWLINE_xXSCREENING INCLUSION CRITERIA:Xx_NEWLINE_xXCHEMOTHERAPY/ADOPTIVE CELL TRANSFER INCLUSION CRITERIA:Xx_NEWLINE_xXINCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANTXx_NEWLINE_xXINCLUSION CRITERIA FOR MAINTENANCE THERAPYXx_NEWLINE_xXPatients with bilateral hydronephrosis unless at least one side has been stented and renal function fulfills the required inclusion criteriaXx_NEWLINE_xXOther protocol defined inclusion criteria could applyXx_NEWLINE_xXAnastomosis or procedure (TME) was performed differently from what was defined in the inclusion criteria.Xx_NEWLINE_xXINCLUSION CRITERIA:Xx_NEWLINE_xXECOG performance status of 0-2 Inclusion Criteria for Phase 2 Sub-study Cohort:Xx_NEWLINE_xXMust meet all inclusion criteria defined in main study and in addition the following criteria must be met:Xx_NEWLINE_xXOther inclusion criteria may applyXx_NEWLINE_xXFurther Inclusion criteria applyXx_NEWLINE_xXFurther inclusion criteria apply.Xx_NEWLINE_xXINCLUSION CRITERIA SEARCH PHASEXx_NEWLINE_xXINCLUSION CRITERIA FOR TRANSPLANT PHASEXx_NEWLINE_xXKnown active Hepatitis B or C infections Inclusion Criteria for Part B: To qualify for enrollment, the following criteria must be met:Xx_NEWLINE_xXINCLUSION CRITERIA FOR COLLECTION AND STORAGE OF PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC)/T CELLSXx_NEWLINE_xXINCLUSION CRITERIA FOR MODIFIED T CELL INFUSIONXx_NEWLINE_xXParticipants with prior therapy, other than therapy specified in inclusion criteriaXx_NEWLINE_xXTumor specific inclusion criteria:Xx_NEWLINE_xXFurther inclusion criteria apply.Xx_NEWLINE_xXSuccessful T cell test expansion (to be performed as part of inclusion criteria until 3 subjects meet all enrollment criteria)Xx_NEWLINE_xXStep I Inclusion Criteria:Xx_NEWLINE_xXStep II Inclusion Criteria:Xx_NEWLINE_xXPROCUREMENT INCLUSION CRITERIA:Xx_NEWLINE_xXTREATMENT INCLUSION CRITERIA:Xx_NEWLINE_xXPatients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:Xx_NEWLINE_xXPatients with a diagnosis of other peripheral T-cell lymphoma (PTCL) histologies other than those specified in the inclusion criteriaXx_NEWLINE_xXConcomitant therapy medications that include corticosteroids (except as indicated in inclusion criteria)Xx_NEWLINE_xXPlatelet count >= 100000/mm^3; blood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXINCLUSION CRITERIA FOR NEWLY DIAGNOSED PATIENTS WITH DIPGXx_NEWLINE_xXCOHORT A (MEDICAL) SPECIFIC INCLUSION:Xx_NEWLINE_xXPatients must fulfill all of the general inclusion criteriaXx_NEWLINE_xXCOHORT B (SURGICAL) SPECIFIC INCLUSION:Xx_NEWLINE_xXPatients must fulfill all the general inclusion criteriaXx_NEWLINE_xXBlood transfusion to meet the inclusion criteria will be allowedXx_NEWLINE_xXInclusion Criteria – Arms B and CXx_NEWLINE_xXPatients failing to meet the inclusion criteriaXx_NEWLINE_xXINCLUSION CRITERIA PRIOR TO TRANSPLANT:Xx_NEWLINE_xXAll patients require an initial diagnosis of a malignant glioma as outlined in the inclusion criteria which must be confirmed at the treating facilityXx_NEWLINE_xXSTRATUM A INCLUSION CRITERIA:Xx_NEWLINE_xXSTRATUM B INCLUSION CRITERIA:Xx_NEWLINE_xXSTAGE I INCLUSION CRITERIA:Xx_NEWLINE_xXSTAGE 2 INCLUSION CRITERIA:Xx_NEWLINE_xXSPECIFIC INCLUSION CRITERIA FOR PHASE IIXx_NEWLINE_xXCentral nervous system (CNS) metastases which do not meet the criteria outlined in inclusion criteriaXx_NEWLINE_xXINCLUSION CRITERIA - MAIN PROTOCOLXx_NEWLINE_xXINCLUSION CRITERIA FOR CONTINUING THERAPY ON THE EXTENSION PHASE:Xx_NEWLINE_xXFailure to meet any of the criteria set forth in inclusionXx_NEWLINE_xXUNRELATED DONOR INCLUSION CRITERIAXx_NEWLINE_xXHistory of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer Open-Label Treatment Period: The following inclusion criteria apply to patients receiving enzalutamide or placebo during double-blind treatment. Eligible patients must meet all inclusion criteria.Xx_NEWLINE_xXPRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXPRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXPatients with locally recurrent sarcoma after surgery alone are eligible for enrollment if other inclusion criteria are met.Xx_NEWLINE_xXTissue or Programmed death-ligand 1 (PD-L1) results available Cohort 1A Inclusion Criteria:Xx_NEWLINE_xXEastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria as listed in the protocol Cohort C Inclusion Criteria:Xx_NEWLINE_xXSLE INCLUSION:Xx_NEWLINE_xXSYSTEMIC SCLEROSIS (SSc) INCLUSION:Xx_NEWLINE_xXMS INCLUSION:Xx_NEWLINE_xXNo prior treatment for diagnoses in inclusion criteria 1Xx_NEWLINE_xXDiagnosis of grade 1 endometrioid endometrial carcinoma without the presence of one of the 3 criteria mentioned in inclusion criteria 1Xx_NEWLINE_xXINCLUSION CRITERIA - ALL PARTICIPANTSXx_NEWLINE_xXINCLUSION CRITERIA - RECIPIENTXx_NEWLINE_xXCentral nervous system (CNS) metastases which do not meet the criteria outlined in the inclusion criteriaXx_NEWLINE_xXHistory of lymphoid malignancy other than those allowed per inclusion criteriaXx_NEWLINE_xXPrior chemotherapy other than inclusion criteriaXx_NEWLINE_xXAdditional inclusion criteria for phase 2 Subjects only:Xx_NEWLINE_xXMesothelin-positive refractory/recurrent MPM (Group 2 only) Inclusion Criteria Part BXx_NEWLINE_xXINCLUSION CRITERIA FOR SBRT vs. RFA RANDOMIZATIONXx_NEWLINE_xXINCLUSION CRITERIA FOR NON-RANDOMIZED SBRT ARMXx_NEWLINE_xXA patient is eligible for second enrollment (allo-cellular therapy) if all of the following inclusion criteria are met:Xx_NEWLINE_xXOther protocol defined inclusion criteria could applyXx_NEWLINE_xXOther protocol defined inclusion criteria could applyXx_NEWLINE_xXREGISTRATION #1 INCLUSION CRITERIAXx_NEWLINE_xXInclusion Clinical Laboratories CriteriaXx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIA: Scheduled for a transurethral resection of bladder tumor (TURBT)Xx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIA: Be a candidate for radical cystectomyXx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIA: Willing to submit tissue for required correlative researchXx_NEWLINE_xXREGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXINCLUSION CRITERIA - HPC-A CELL DONOR: Family member (first degree relatives)Xx_NEWLINE_xXINCLUSION CRITERIA - HPC-A CELL DONOR: Not breast feedingXx_NEWLINE_xXCentral nervous system (CNS) metastases which do not meet the criteria outlined in inclusion criteriaXx_NEWLINE_xXTumor invasion of bone (also see inclusion criteria)Xx_NEWLINE_xXTumors in locations other than those specified in inclusion criteriaXx_NEWLINE_xXGeneral Inclusion CriteriaXx_NEWLINE_xXVAS Pain Score > 60mm on 100mm scale. -Impending Fracture-Specific Inclusion CriteriaXx_NEWLINE_xXINCLUSION CRITERIA FOR SCREENING:Xx_NEWLINE_xXPatients who do not meet the above inclusion criteria will not receive leukapheresisXx_NEWLINE_xXINCLUSION CRITERIA FOR TREATMENT:Xx_NEWLINE_xXINCLUSION CRITERIA - INITIAL ENROLLMENTXx_NEWLINE_xXINCLUSION CRITERIA - MAINTENANCE THERAPY AFTER HSCTXx_NEWLINE_xXINCLUSION CRITERIA FOR TRANSPLANT RECIPIENTXx_NEWLINE_xXINCLUSION CRITERIA FOR HAPLOIDENTICAL DONORXx_NEWLINE_xXINCLUSION CRITERIA (ALL SUBJECTS)Xx_NEWLINE_xXINCLUSION CRITERIA (EXPANSION PHASE ONLY)Xx_NEWLINE_xXConcurrent treatment for cancer, with specific exceptions noted in inclusion criteriaXx_NEWLINE_xXPrior systemic anticancer treatment for advanced HCC (except for sorafenib as described in the inclusion criteria)Xx_NEWLINE_xXOther protocol defined inclusion criteria could applyXx_NEWLINE_xXInclusion Criteria for Part 1 and Part 2Xx_NEWLINE_xXOther Inclusion criteria for Part 1Xx_NEWLINE_xXOther Inclusion criteria for Part 2Xx_NEWLINE_xXInclusion Criteria for Part 3Xx_NEWLINE_xXThe inclusion criteria for Part 3 will be based on emerging data from Parts 1 and 2 and will be specified in an amendment.Xx_NEWLINE_xXOther inclusion criteria may applyXx_NEWLINE_xXOther protocol defined inclusion criteria may apply.Xx_NEWLINE_xXParticipants must meet the inclusion criteria outlined in the respective parent protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296)Xx_NEWLINE_xXAll adverse events from the procedure have resolved or have been deemed irreversible and the patient meets inclusion criteria.Xx_NEWLINE_xXKey Inclusion Criteria:\n\n          -  Individuals in the primary Phase 3 study (Study GS-US-312-0116) who are compliant\n\n          -  Tolerating primary study therapy\n\n        Note: Other protocol defined Inclusion/Exclusion criteria may apply.Xx_NEWLINE_xXOther inclusion criteria may applyXx_NEWLINE_xXPHASE II REGISTRATION - INCLUSION CRITERIAXx_NEWLINE_xXTherapy with any other standard or investigational treatment for hematologic malignancy (except hydroxyurea, as mentioned in the inclusion criteria)Xx_NEWLINE_xXCan take oral med Part 2 Inclusion Criteria:Xx_NEWLINE_xXCan take oral med Part 3 Inclusion Criteria:Xx_NEWLINE_xXCan take oral med Part 4 Inclusion Criteria:Xx_NEWLINE_xXThe clinical status of the patient at inclusion is one of the following:Xx_NEWLINE_xXCOHORT 1 INCLUSION CRITERIA FOR APHERESIS/TUMOR BIOPSY PORTION OF THE TRIAL (closed to enrollment as of 6/22/13):Xx_NEWLINE_xXCOHORT 1 INCLUSION CRITERIA FOR IMMUNOTHERAPY PORTION OF THE TRIAL (closed to enrollment as of 6/22/13):Xx_NEWLINE_xXCOHORT 2 INCLUSION CRITERIA:Xx_NEWLINE_xXMust meet all inclusion and exclusion criteriaXx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXINCLUSION CRITERIA FOR SCREENING:Xx_NEWLINE_xXINCLUSION CRITERIA FOR TREATMENT:Xx_NEWLINE_xXINCLUSION CRITERIA FOR PHYSICIANSXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTSXx_NEWLINE_xXCurrently receiving (or scheduled to receive) radiation treatment for a cancer listed in the inclusion criteriaXx_NEWLINE_xXPATIENT INCLUSION: Have an identified caregiver who is also willing to participateXx_NEWLINE_xXINCLUSION CRITERIA FOR CROSSOVER THERAPYXx_NEWLINE_xXPHASE I INCLUSION CRITERIA:Xx_NEWLINE_xXPHASE II INCLUSION CRITERIA:Xx_NEWLINE_xXPHASE III INCLUSION CRITERIA:Xx_NEWLINE_xXIf they are not patients of Massey Cancer Center or do not meet the inclusion criteria listed aboveXx_NEWLINE_xXINCLUSION CRITERIA-PATIENTSXx_NEWLINE_xXINCLUSION CRITERIA-FCGsXx_NEWLINE_xXINCLUSION CRITERIA FOR PARENTS: Parents of children who are aged 2-24 yearsXx_NEWLINE_xXINCLUSION CRITERIA FOR PARENTS: Parents of children who have been diagnosed with new malignancy between 1-10 weeks priorXx_NEWLINE_xXINCLUSION CRITERIA FOR PARENTS: Cognitively able to participate in interactive interviewsXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Child aged 2-24 yearsXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Child who have been diagnosed with a new malignancy between 1-10 weeks priorXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Child who are scheduled to receive cancer-directed therapy at Seattle Children's HospitalXx_NEWLINE_xXINCLUSION - STUDY 2: The inclusion/exclusion criteria follows similar criteria for study #1 except only patients with confirmed peripheral neuropathy (vibration perception threshold [VPT] big toe greater than 25 volt) will be included; patients who have completed clinical study 1 would be eligible for study 2 if develop CIPN as defined by VPT assessmentXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENT PARTICIPANTSXx_NEWLINE_xXINCLUSION CRITERIA FOR CAREGIVER PARTICIPANTSXx_NEWLINE_xXCaregiver inclusion criteria:\r\n* Adults (>= 21)\r\n* Family member or friend of an eligible patientXx_NEWLINE_xXPARTNER: Female/male intimate partner of a young breast cancer survivor who meets the above YBCS inclusion criteriaXx_NEWLINE_xXEXERCISE INCLUSION CRITERIA:Xx_NEWLINE_xXCROSSOVER RE-REGISTRATION - INCLUSION CRITERIAXx_NEWLINE_xXProviding the majority of the informal (unpaid) care during RT for a patient meeting inclusion criteriaXx_NEWLINE_xXINCLUSION CRITERIA FOR FOCUS GROUPS (PHASE I)Xx_NEWLINE_xXINCLUSION CRITERIA FOR PILOT-TESTING (PHASE II)Xx_NEWLINE_xXSTRATEGISTS INCLUSION CRITERIAXx_NEWLINE_xXBlood transfusion to meet the inclusion criteria will not be allowedXx_NEWLINE_xXPATIENT INCLUSION CRITERIA:Xx_NEWLINE_xXCAREGIVER INCLUSION CRITERIA:Xx_NEWLINE_xXMeet all inclusion criteria aboveXx_NEWLINE_xXReady to use reliable contraceptive procedures Inclusion Criteria Specific to HCC (Arm A and Arm F):Xx_NEWLINE_xXAntiviral therapy per local standard-of-care if active hepatitis B virus (HBV) Inclusion Criteria Specific to Arm A (Patients must also meet all of the following specific inclusion criteria to be eligible for enrollment in Arm A:)Xx_NEWLINE_xXAnti-viral therapy per local standard-of-care if active hepatitis B virus (HBV). Inclusion Criteria Specific to Arm F (Patients must also meet all of the following specific inclusion criteria to be eligible for enrollment in Arm F:)Xx_NEWLINE_xXAnti-viral therapy per local standard-of-care if active hepatitis B virus (HBV). Inclusion Criteria Specific to Gastric Cancer (Arm B) (Patients must also meet all of the following specific inclusion criteria to be eligible for enrollment in Arm B:)Xx_NEWLINE_xXAbsence of HER2 expression documented as in situ hybridization (ISH) negative on previously collected and assessed tumor tissue upon initial diagnosis of disease Inclusion criteria specific to metastatic pancreatic cancer (Arm C) (Patients must also meet all of the following specific inclusion criteria to be eligible for enrollment in Arm C:)Xx_NEWLINE_xXNo previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease Inclusion Criteria Specific to mEC (Arm E) (Patients must also meet all of the following specific inclusion criteria to be eligible for enrollment in Arm E:)Xx_NEWLINE_xXECOG ? 3 Phase 2 Inclusion Criteria:Xx_NEWLINE_xXINCLUSION CRITERIA FOR GROUP 2A AND 2BXx_NEWLINE_xXINCLUSION CRITERIA-PATIENTSXx_NEWLINE_xXINCLUSION CRITERIA-CAREGIVERSXx_NEWLINE_xXPatients who will be enrolled on the observational arm should meet the 2nd, 3rd, and 4th inclusion criteria onlyXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Admitted to 6E with suspected or actual new diagnosis of leukemia or lymphoma within the past 24 hoursXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: English-speakingXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Completed education to at least the 6th grade levelXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: No significant auditory or visual deficits with corrective devicesXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Physiologically stableXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: Not at end of lifeXx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS: No alterations in mental statusXx_NEWLINE_xXINCLUSION CRITERIA FOR FAMILY MEMBERS: Willing to view DVD and read education bookletXx_NEWLINE_xXINCLUSION CRITERIA FOR FAMILY MEMBERS: Selected by patient to participateXx_NEWLINE_xXINCLUSION CRITERIA FOR FAMILY MEMBERS: English speakingXx_NEWLINE_xXINCLUSION CRITERIA FOR FAMILY MEMBERS: No significant auditory or visual deficits with corrective devicesXx_NEWLINE_xXINCLUSION CRITERIA FOR FAMILY MEMBERS: No alterations in mental statusXx_NEWLINE_xXINCLUSION CRITERIA FOR FAMILY MEMBERS: Completed education to at least the 6th grade levelXx_NEWLINE_xXUsing the same inclusion criteria as Stage 1 a convenience sample of 30 different HNC survivors will be recruitedXx_NEWLINE_xXAll other postmenopausal women are eligible for inclusion in the biennial screening regimenXx_NEWLINE_xXREADER STUDY INCLUSIONXx_NEWLINE_xXPRE-REGISTRATION-INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION/RANDOMIZATION INCLUSION CRITERIA:Xx_NEWLINE_xXPRE-REGISTRATION INCLUSIONXx_NEWLINE_xXREGISTRATION INCLUSIONXx_NEWLINE_xXPRE-REGISTRATION INCLUSION:Xx_NEWLINE_xXREGISTRATION INCLUSION:Xx_NEWLINE_xXMeets all inclusion criteria outlined in Aim 1Xx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXLaboratory (lab) results do not meet inclusion criteriaXx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXAny lab results that do not meet inclusion criteria after the Screen 1 blood testsXx_NEWLINE_xXPHASE II: Meet all the Phase 1 inclusion criteriaXx_NEWLINE_xXINCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT)Xx_NEWLINE_xXINCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION)Xx_NEWLINE_xXDONOR INCLUSION CRITERIAXx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION/RANDOMIZATION INCLUSION CRITERIAXx_NEWLINE_xXInclusion criteria for screening RPFNAXx_NEWLINE_xXInclusion criteria for intervention phaseXx_NEWLINE_xXDRIVERS INCLUSION CRITERIAXx_NEWLINE_xXPatient plans to receive concurrent chemotherapy, other than the regimens specified in the inclusion criteriaXx_NEWLINE_xXSubject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet all of the inclusion and none of the exclusion criteriaXx_NEWLINE_xXAdditional Inclusion Criteria Specific for Arm A:Xx_NEWLINE_xXAdditional Inclusion Criteria Specific for Arm B:Xx_NEWLINE_xXAdditional Inclusion Criteria Specific for Arm C:Xx_NEWLINE_xXPRE-REGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXREGISTRATION INCLUSION CRITERIAXx_NEWLINE_xXPatients failing to meet the inclusion criteriaXx_NEWLINE_xXGENERAL INCLUSION CRITERIAXx_NEWLINE_xXSubjects who do not meet the above mentioned inclusion criteriaXx_NEWLINE_xXOne of the following inclusion criteria must be true for patient to be eligible for enrollment:Xx_NEWLINE_xXINCLUSION CRITERIA (INITIAL 10 PATIENTS WITH METASTATIC PROSTATE CANCER)Xx_NEWLINE_xXHEALTHY VOLUNTEERS (Group 4): Must meet inclusion criteria for “all participants” described aboveXx_NEWLINE_xXINCLUSION CRITERIA: MEN WITH UNTREATED PROSTATE CANCERXx_NEWLINE_xXINCLUSION CRITERIA: FOR MEN WITH PRESUMED PROSTATE CANCER RELAPSEXx_NEWLINE_xXINCLUSION CRITERIA FOR OPEN-ACCESS: Female participants of childbearing age must not be lactatingXx_NEWLINE_xXINCLUSION CRITERIA FOR ORAL LESION AND NORMAL TISSUEXx_NEWLINE_xXINCLUSION CRITERIA FOR DRY MOUTH STUDYXx_NEWLINE_xXINCLUSION CRITERIA FOR GUM STUDYXx_NEWLINE_xXInclusion criteria for Aim 1:Xx_NEWLINE_xXInclusion criteria for Aim 2:Xx_NEWLINE_xXBiopsy does not meet inclusion criteriaXx_NEWLINE_xXOther protocol defined inclusion criteria could applyXx_NEWLINE_xXAll subjects enrolled into either Part 1 or Part 2 must meet all of the following inclusion criteria to be eligible:Xx_NEWLINE_xXSubject must give written informed consent. Part B, Inclusion criteria All inclusion criteria as for Part A, except for inclusion criterion 2 which is replaced by:Xx_NEWLINE_xXSTEP 1: INCLUSION CRITERIA FOR TUMOR COLLECTIONXx_NEWLINE_xXSTEP 2: INCLUSION CRITERIA PRIOR TO RANDOMIZATIONXx_NEWLINE_xXOther Inclusion Criteria May ApplyXx_NEWLINE_xXPrevious inclusion in the current studyXx_NEWLINE_xXCommon inclusion criterionXx_NEWLINE_xXInclusion criterion for normal cohortXx_NEWLINE_xXINCLUSION CRITERIA - FOR MALE COHORTXx_NEWLINE_xXINCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Good health conditions or without significant diseases, according to best medical judgementXx_NEWLINE_xXINCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: If breastfeeding, must be willing to discard breastmilk for 24 hours following zolpidemXx_NEWLINE_xXINCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Ability to swallow study medicationXx_NEWLINE_xXHEALTHY VOLUNTEER INCLUSION CRITERIA:Xx_NEWLINE_xXPANCREATIC CANCER PATIENT INCLUSION CRITERIA:Xx_NEWLINE_xXSITE INCLUSION CRITERIA:Xx_NEWLINE_xXPATIENT INCLUSION CRITERIA:Xx_NEWLINE_xXCLINICIAN PARTICIPANTS INCLUSION CRITERIA:Xx_NEWLINE_xXPATIENT PARTICIPANTS INCLUSION CRITERIA:Xx_NEWLINE_xXGARAGE INCLUSION:Xx_NEWLINE_xXDRIVER INCLUSION:Xx_NEWLINE_xXNot currently receiving radiation treatment for a cancer listed in the arm-specific inclusion criteria (Arms 2 and 3)Xx_NEWLINE_xXTRIAL INCLUSION:Xx_NEWLINE_xXPATIENT INCLUSION:Xx_NEWLINE_xXHEALTH CARE PROVIDER INCLUSION CRITERIA:Xx_NEWLINE_xXCHART AUDIT INCLUSION CRITERIA (BASELINE):Xx_NEWLINE_xXCHART AUDIT INCLUSION CRITERIA (POST-INTERVENTION)Xx_NEWLINE_xXCriteria 10, Other Inclusion Criteria May Apply.Xx_NEWLINE_xXOther Inclusion Criteria May ApplyXx_NEWLINE_xXCohort 4 (severe): Bilirubin > 3 × ULN; any AST Exception to Inclusion Criterion #5 for Subjects with Normal Hepatic Function: All subjects enrolled with normal hepatic function (N=10) must meet all inclusion criteria as outlined with the exception of Inclusion Criterion #5, which should be substituted with the following criterion to be enrolled into the study:Xx_NEWLINE_xX